Polpharma SA:企業の戦略的SWOT分析

◆英語タイトル:Polpharma SA - Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1777
◆発行会社(調査会社):GlobalData
◆発行日:2019年11月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ポーランド
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Polpharma SA – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Polpharma SA (Polpharma) undertakes the research, manufacture and marketing of generic drugs, prescription drugs and over the counter medications. It provides drugs in cardiology, gastroenterology and neurology areas. The company also manufactures over the counter (OTC) medications, dietary supplements, cosmetic products, medical devices and phyto-pharmaceuticals as well as active pharmaceutical ingredients (APIs). Polpharma has manufacturing plants in Russia, Poland and Kazakhstan. The company operates in Central and Eastern Europe, the Caucasus and Central Asia markets. Polpharma group includes Santo, Medana SA, Akrikhin Pharmaceuticals, Polfa Warszawa S.A. Polpharma is headquartered in Starogard Gdanski, Poland.

Polpharma SA Key Recent Developments

Sep 03,2019: Sandoz licences proposed multiple sclerosis biosimilar from Polpharma
Jan 02,2019: IMCoPharma: Registrations of APIs in Uzbekistan

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Polpharma SA – Key Facts
Polpharma SA – Key Employees
Polpharma SA – Major Products and Services
Polpharma SA – History
Polpharma SA – Company Statement
Polpharma SA – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Polpharma SA – Business Description
Polpharma SA – Corporate Strategy
Polpharma SA – SWOT Analysis
SWOT Analysis – Overview
Polpharma SA – Strengths
Polpharma SA – Weaknesses
Polpharma SA – Opportunities
Polpharma SA – Threats
Polpharma SA – Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Polpharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Polpharma SA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Polpharma SA, Recent Deals Summary
Section 4 – Company’s Recent Developments
Sep 03, 2019: Sandoz licences proposed multiple sclerosis biosimilar from Polpharma
Jan 02, 2019: IMCoPharma: Registrations of APIs in Uzbekistan
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List of Tables
Polpharma SA, Key Facts
Polpharma SA, Key Employees
Polpharma SA, Major Products and Services
Polpharma SA, History
Polpharma SA, Other Locations
Polpharma SA, Subsidiaries
Polpharma SA, Joint Venture
Polpharma SA, Key Competitors
Polpharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Polpharma SA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Polpharma SA, Recent Deals Summary

List of Figures
Polpharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Polpharma SA, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Polpharma SA:企業の戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SteadyMed Therapeutics Inc:医療機器:M&Aディール及び事業提携情報
    Summary SteadyMed Therapeutics Inc (SteadyMed), a subsidiary of SteadyMed Ltd is a pharmaceutical company that develops and commercializes therapeutic product candidates. The company provides patchpump, a customizable, pre-filled, and pre-programmed disposable parenteral delivery platform for large …
  • Plansee Holding AG:企業の戦略・SWOT・財務情報
    Plansee Holding AG - Strategy, SWOT and Corporate Finance Report Summary Plansee Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Sete Brasil Participacoes SA:企業の戦略的SWOT分析
    Sete Brasil Participacoes SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Minesto AB (MINEST):電力:M&Aディール及び事業提携情報
    Summary Minesto AB (Minesto) is a marine energy technology developer. The company offers ervices such as renewable energy solutions, tidal power plants operations and management, power generation, and deep green technology solutions. It also provides control-system design, hydrodynamics, simulation, …
  • Insurance and Care NSW:企業の戦略的SWOT分析
    Insurance and Care NSW - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Banca Popolare di Spoleto S.p.A.:企業の戦略・SWOT・財務情報
    Banca Popolare di Spoleto S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Banca Popolare di Spoleto S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Hill-Rom Holdings Inc (HRC)-医療機器分野:企業M&A・提携分析
    Summary Hill-Rom Holdings Inc (Hill-Rom) is a medical technology company that offers patient support systems, surgical solutions and other front line care products. The company’s major products and services include patient care systems; safe mobility and handling solutions; non-invasive therapeutic …
  • Aurobindo Pharma Ltd (AUROPHARMA)-製薬・医療分野:企業M&A・提携分析
    Summary Aurobindo Pharma Ltd (Aurobindo Pharma) is a pharmaceutical company which develops, manufactures and exports formulations and active pharmaceutical ingredients (API's). Its products portfolio include active pharma ingredients, formulations, antibiotics, anti-retrovirals, anti- allergics, gas …
  • Robert Half International Inc. (RHI):企業の財務・戦略的SWOT分析
    Robert Half International Inc. (RHI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Verax Biomedical Inc-製薬・医療分野:企業M&A・提携分析
    Summary Verax Biomedical Inc (Verax) is a medical device company that develops rapid tests for the detection of bacterial contaminants in tissues for transplantation, blood components, and cellular therapies. The company’s products comprise platelet pgd test, red cell pgd test and cell therapy PGD t …
  • Neurolixis Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Neurolixis Inc (Neurolixis) is an early-stage biopharmaceutical company that discovers and develops novel drugs for the treatment of human central nervous system disorders. The company’s pipeline product portfolio includes NLX-112, a drug candidate intended for the treatment of L-DOPA-induce …
  • Ebara Corp (6361):企業の財務・戦略的SWOT分析
    Ebara Corp (6361) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Gexa Energy LP:企業の戦略的SWOT分析
    Gexa Energy LP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • SiteOne Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary SiteOne Therapeutics Inc (SiteOne) is a developer of novel therapeutics and diagnostics for the treatment of acute and chronic pain. The company’s lead therapeutic candidates comprise selective inhibitors of a voltage-gated sodium ion channel, Na 1.7 which helps to generate and conduct pain …
  • Abzena Plc (ABZA):企業の財務・戦略的SWOT分析
    Summary Abzena Plc (Abzena), formerly Polytherics Group Ltd, is a life science company that provides complementary services and technologies to enable the selection, development and manufacture of biopharmaceuticals products based on antibodies and other proteins. The company's technologies include …
  • Charter Hall Group:企業のM&A・事業提携・投資動向
    Charter Hall Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Charter Hall Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Rubicon Genomics Inc-医療機器分野:企業M&A・提携分析
    Summary Rubicon Genomics Inc (Rubicon Genomics), a subsidiary of the Takara Bio Group is a provider of pre-analytical amplification technologies. The company offers various types of kits for whole genome sequencing (WGS), whole exome sequencing (WES), targeted sequencing, copy number variation (CNV) …
  • HL Global Enterprises Limited:企業の戦略・SWOT・財務情報
    HL Global Enterprises Limited - Strategy, SWOT and Corporate Finance Report Summary HL Global Enterprises Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • BiosanaPharma BV:製薬・医療:M&Aディール及び事業提携情報
    Summary BiosanaPharma BV (Biosana) is a biotechnology company engaged in the development of monoclonal antibody biologicals (mAbs), biosimilars and biobetters. Its pipeline products include BP001: biosimilar of Omalizumab (anti-allergy); BP002: biosimilar of Denosumab (anti-osteoporosis); BOX001: or …
  • Piramal Enterprises Ltd (PEL):医療機器:M&Aディール及び事業提携情報
    Summary Piramal Enterprises Ltd (PEL), is a provider of medicines and healthcare finance services. The company offers products such as Critical Care, Consumer Care, BST-CarGel, Phyto Medicines, Anaesthesias, Orthopedic medicines, Halothane, Isoflurane , Sevoflurane and other OTC related medicines. I …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆